Harmony Biosciences Holdings, Inc.(HRMY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

HRMY Harmony Biosciences Holdings, Inc.

Market Closed 06-28 16:00:00 EDT

30.17

-1.31

-4.16%

盘后30.17

+0.000.00%

19:49 EDT

High31.89	Low30.13	Vol802.79K
Open31.60	D1 Closing31.48	Amplitude5.61%
Mkt Cap1.71B	Tradable Cap1.05B	Total Shares56.79M
T/O24.41M	T/O Rate2.32%	Tradable Shares34.64M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"HRMY","market":"US","secType":"STK","nameCN":"Harmony Biosciences Holdings, Inc.","latestPrice":30.17,"timestamp":1719604800000,"preClose":31.48,"halted":0,"volume":802785,"hourTrading":{"tag":"盘后","latestPrice":30.17,"preClose":30.17,"latestTime":"19:49 EDT","volume":197706,"amount":5965084.686084,"timestamp":1719618565831},"delay":0,"floatShares":34638946,"shares":56791861,"eps":2.317228,"marketStatus":"Market Closed","change":-1.31,"latestTime":"06-28 16:00:00 EDT","open":31.6,"high":31.89,"low":30.125,"amount":24414316.686839998,"amplitude":0.056067,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.317228,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1719820800000},"marketStatusCode":7,"adr":0,"listingDate":1597809600000,"exchange":"NASDAQ","adjPreClose":31.48,"postHourTrading":{"tag":"盘后","latestPrice":30.17,"preClose":30.17,"latestTime":"19:49 EDT","volume":197706,"amount":5965084.686084,"timestamp":1719618565831},"volumeRatio":1.275325,"impliedVol":0.6424,"impliedVolPercentile":0.4206},"requestUrl":"/m/hq/s/HRMY","defaultTab":"news","newsList":[{"id":"2446884903","title":"Harmony Biosciences Says FDA Denies Short Seller Claims Over Narcolepsy Drug Safety","url":"https://stock-news.laohu8.com/highlight/detail?id=2446884903","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2446884903?lang=en_us&edition=fundamental","pubTime":"2024-06-25 21:43","pubTimestamp":1719322980,"startTime":"0","endTime":"0","summary":"Harmony Biosciences Holdings on Tuesday said the U.S. Food and Drug Administration denied a citizen petition filed by short seller which claimed there were safety issues around its narcolepsy drug, Wakix.The pharmaceutical company said the FDA rejected the petition which claimed Wakix was neither safe nor effective for the treatment of excessive daytime sleepiness, or EDS, and cataplexy in adults with narcolepsy. The denied requests also included the withdrawal for all indications and an immediate alert distribution to prescribers.The company said the regulator didn't receive information which changed the favorable benefit-risk profile of the drug.On Friday the FDA expanded Wakix's indication to include the treatment of EDS in pediatric patients 6 years of age and older with narcolepsy. \"We appreciate the agency's careful review of the unfounded claims in the petition and its definitive action to deny the claims and resolve any potential doubt about the favorable benefit-risk profile o","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HRMY"],"gpt_icon":0},{"id":"2446845471","title":"BRIEF-Harmony Biosciences Confirm Our Outlook Wakix Represents Billion-Dollar Plus Market Opportunity In Adult Narcolepsy","url":"https://stock-news.laohu8.com/highlight/detail?id=2446845471","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2446845471?lang=en_us&edition=fundamental","pubTime":"2024-06-25 21:13","pubTimestamp":1719321223,"startTime":"0","endTime":"0","summary":"June 25  - Harmony Biosciences Holdings Inc :   * HARMONY BIOSCIENCES: CONFIRM OUR OUTLOOK WAKIX REPRESENTS BILLION-DOLLAR PLUS MARKET OPPORTUNITY IN ADULT NARCOLEPSY   * HARMONY BIOSCIENCES: ON TRACK TOWARD FILING SNDA FOR WAKIX IN IDIOPATHIC HYPERSOMNIA LATER THIS YEARSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HRMY"],"gpt_icon":0},{"id":"2446084876","title":"HARMONY BIOSCIENCES ACKNOWLEDGES U.S. FOOD & DRUG ADMINISTRATION (FDA) ACTION DENYING THE CITIZEN PETITION FOR WAKIX® (PITOLSIANT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2446084876","media":"PR Newswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2446084876?lang=en_us&edition=fundamental","pubTime":"2024-06-25 20:05","pubTimestamp":1719317100,"startTime":"0","endTime":"0","summary":"FDA confirms the favorable benefit-risk profile of WAKIX. Harmony Biosciences focused on continuing to advance its pipeline assets across three rare CNS franchises; anticipates at least one new product or indication launch annually over the next five years. Looking ahead, we confirm our outlook that WAKIX represents a billion-dollar plus market opportunity in adult narcolepsy alone, and we are well on our way to achieving further growth in the pitolisant franchise. We are also on track toward filing an sNDA for WAKIX in idiopathic hypersomnia later this year . In anticipation of the confirmation of the favorable benefit-risk profile of WAKIX, we have already been working on the next-generation formulations of pitolisant to address unmet medical needs. These formulations are designed to provide meaningful improvement, such as an enhanced pharmacokinetic  profile and higher dosage range to drive greater efficacy. These innovations are expected togenerate new IP to extend the pitolisant f","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ZM_gpg5vbHlXilZ5b8i.8A--~B/aD0zMTI7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f7db46efb59308fee209dd80bac82676","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ZM_gpg5vbHlXilZ5b8i.8A--~B/aD0zMTI7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f7db46efb59308fee209dd80bac82676"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/harmony-biosciences-acknowledges-u-food-120500160.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/harmony-biosciences-acknowledges-u-food-120500160.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4181","BK4007","BK4024","PK","FOR","BK4218","DRUG","HRMY"],"gpt_icon":0},{"id":"2446889481","title":"Goldman Sachs Keeps Their Sell Rating on Harmony Biosciences Holdings (HRMY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2446889481","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2446889481?lang=en_us&edition=fundamental","pubTime":"2024-06-25 03:55","pubTimestamp":1719258915,"startTime":"0","endTime":"0","summary":"In a report released today, Corinne Johnson from Goldman Sachs maintained a Sell rating on Harmony Biosciences Holdings (HRMY – Research Report). T...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/goldman-sachs-keeps-their-sell-rating-on-harmony-biosciences-holdings-hrmy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/goldman-sachs-keeps-their-sell-rating-on-harmony-biosciences-holdings-hrmy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HRMY"],"gpt_icon":0},{"id":"2446002907","title":"Harmony Biosciences Price Target Maintained With a $52.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2446002907","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2446002907?lang=en_us&edition=fundamental","pubTime":"2024-06-25 01:12","pubTimestamp":1719249120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/HRMY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 24, 2024 13:12 ET (17:12 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HRMY"],"gpt_icon":0},{"id":"2446004796","title":"7 Biotech Stocks to Buy on the Dip: June 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2446004796","media":"InvestorPlace","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2446004796?lang=en_us&edition=fundamental","pubTime":"2024-06-25 00:56","pubTimestamp":1719248170,"startTime":"0","endTime":"0","summary":"With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://investorplace.com/2024/06/7-biotech-stocks-to-buy-on-the-dip-june-2024/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investorplace_stock_picks","symbols":["GMAB","PSQ","MNQmain","RPRX","TQQQ","BK4505","AMPH","COLL","BK4139","BK4563","QLD",".IXIC","SQQQ","BK4557","QID","BK4099","PLRX","NQmain","BK4588","BK4523","BK4007","TTM","BK4159","RGNX","BK4585","HRMY","CAGR","QQQ"],"gpt_icon":0},{"id":"2446097070","title":"Harmony wins Wakix label extension to include sleepiness in pediatric patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2446097070","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2446097070?lang=en_us&edition=fundamental","pubTime":"2024-06-24 22:56","pubTimestamp":1719240961,"startTime":"0","endTime":"0","summary":"The U.S. FDA has expanded the label of Harmony Biosciences'  Wakix  to treat excessive daytime sleepiness in patients as young as six years old with narcolepsy. However, the agency issued a Complete Response Letter to a supplemental New Drug Application for the drug for cataplexy in pediatric patients.  The extension approval was based on results from a Phase 3 study conducted by Bioprojet, which developed Wakix.","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/486815668/image_486815668.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/486815668/image_486815668.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4118420-harmony-wins-wakix-label-extension-include-sleepiness-pediatric-patients","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4007","HRMY"],"gpt_icon":0},{"id":"2445008563","title":"Harmony Biosciences Receives Buy Rating on FDA Approval and Promising Pipeline Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=2445008563","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2445008563?lang=en_us&edition=fundamental","pubTime":"2024-06-24 22:35","pubTimestamp":1719239720,"startTime":"0","endTime":"0","summary":"Harmony Biosciences Holdings (HRMY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ami Fad...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/harmony-biosciences-receives-buy-rating-on-fda-approval-and-promising-pipeline-developments?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/harmony-biosciences-receives-buy-rating-on-fda-approval-and-promising-pipeline-developments?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","HRMY"],"gpt_icon":0},{"id":"2445079155","title":"Harmony Biosciences Says FDA Approves Supplemental NDA for Pediatric Narcolepsy Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2445079155","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2445079155?lang=en_us&edition=fundamental","pubTime":"2024-06-24 20:56","pubTimestamp":1719233815,"startTime":"0","endTime":"0","summary":"Harmony Biosciences Holdings  said Monday that its supplemental new drug application for WAKIX tablets to treat excessive daytime sleepiness in narcolepsy pediatric patients aged 6 years and older has been approved by the US Food and Drug Administration.The approval follows a phase 3 study demonstrating safety and efficacy of pitolisant in patients aged 6 years to under 18 years, the company said.Shares of the company were up 2.8% in Monday premarket activity.Price: 30.98, Change: +0.85, Percent Change: +2.82","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HRMY"],"gpt_icon":0},{"id":"2445027587","title":"BRIEF-Harmony Biosciences Receives U.S. Food And Drug Administration Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2445027587","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2445027587?lang=en_us&edition=fundamental","pubTime":"2024-06-24 19:11","pubTimestamp":1719227517,"startTime":"0","endTime":"0","summary":"June 24  - Harmony Biosciences Holdings Inc :   * HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION APPROVAL FOR WAKIX  IN PEDIATRIC PATIENTS WITH NARCOLEPSY   * HARMONY BIOSCIENCES: PLAN TO DISCUSS WITH AGENCY PATH FORWARD FOR CATAPLEXY INDICATION IN PEDIATRIC NARCOLEPSY PATIENTSSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HRMY"],"gpt_icon":0},{"id":"2445488020","title":"HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION APPROVAL FOR WAKIX® (PITOLISANT) IN PEDIATRIC PATIENTS WITH NARCOLEPSY","url":"https://stock-news.laohu8.com/highlight/detail?id=2445488020","media":"PR Newswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2445488020?lang=en_us&edition=fundamental","pubTime":"2024-06-24 19:00","pubTimestamp":1719226800,"startTime":"0","endTime":"0","summary":"WAKIX is the first-and-only FDA-approved non-scheduled treatment option for excessive daytime sleepiness in pediatric patients 6 years of age and older with narcolepsy. FDA granted priority review of the sNDA in February 2024. PLYMOUTH MEETING, Pa., June 24, 2024 /PRNewswire/ -- Harmony Biosciences  today announced that the U.S. Food and Drug Administration  has approved its supplemental New Drug Application  for WAKIX  tablets for the treatment of excessive daytime sleepiness  in pediatric patients 6 years of age and older with narcolepsy. The FDA separated the submission into two sNDAs for administrative purposes to issue an approval for the treatment of EDS and a complete response for the treatment of cataplexy in pediatric patients  with narcolepsy.WAKIX was first approved by the FDA in August 2019 for the treatment of EDS in adult patients with narcolepsy, followed by FDA approval for the treatment of cataplexy in adult patients with narcolepsy in October 2020. A first-in-class tr","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ZM_gpg5vbHlXilZ5b8i.8A--~B/aD0zMTI7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f7db46efb59308fee209dd80bac82676","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ZM_gpg5vbHlXilZ5b8i.8A--~B/aD0zMTI7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f7db46efb59308fee209dd80bac82676"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/harmony-biosciences-receives-u-food-110000009.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/harmony-biosciences-receives-u-food-110000009.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FOR","HRMY","DRUG"],"gpt_icon":0},{"id":"2445876524","title":"Harmony Biosciences Initiated at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2445876524","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2445876524?lang=en_us&edition=fundamental","pubTime":"2024-06-21 22:37","pubTimestamp":1718980620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/HRMY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 21, 2024 10:37 ET (14:37 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","HRMY"],"gpt_icon":0},{"id":"2445754702","title":"Harmony Bio gains as Citi starts at Buy on risk-reward setup","url":"https://stock-news.laohu8.com/highlight/detail?id=2445754702","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2445754702?lang=en_us&edition=fundamental","pubTime":"2024-06-21 20:59","pubTimestamp":1718974757,"startTime":"0","endTime":"0","summary":"Harmony Biosciences (NASDAQ:HRMY) traded higher in the premarket Friday after Citi launched its coverage with a Buy rating and a $48 per share target, noting that with little credit attributed to its ","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1651064790/image_1651064790.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1651064790/image_1651064790.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4117902-harmony-bio-stock-gains-citi-starts-buy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["HRMY","BK4007"],"gpt_icon":0},{"id":"2445364397","title":"Praxis Precision Medicines (PRAX) Surges 6.4%: Is This an Indication of Further Gains?","url":"https://stock-news.laohu8.com/highlight/detail?id=2445364397","media":"Zacks","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2445364397?lang=en_us&edition=fundamental","pubTime":"2024-06-21 15:32","pubTimestamp":1718955120,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines, Inc.  shares soared 6.4% in the last trading session to close at $40.11. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 11.4% loss over the past four weeks.The sudden rise in the stock price was observed after its competitor firm, Jazz Pharmaceuticals, announced the failure of its mid-stage study evaluating an investigational candidate,suvecaltamide,in adult patients with essential tremor . Praxis’ most advanced product candidate, ulixacaltamide , is currently being evaluated in a late-stage study for the ET indication. Topline data from the phase III study is expected in the second half of 2024. The stock price gain signifies that the investors are optimistic about ulixacaltamide’s potential to succeed in the late-stage study.For Praxis Precision Medicines, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn'","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Kb5frpg4JkRo6YH3O5eYuQ--~B/aD05MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/2aa8a932141f86e96fa74bdc1ee833a9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Kb5frpg4JkRo6YH3O5eYuQ--~B/aD05MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/2aa8a932141f86e96fa74bdc1ee833a9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/praxis-precision-medicines-prax-surges-073200558.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4007","HRMY","PRAX","BK4581","BK4144","BK4588","ET","BK4561","BK4590","BK4139"],"gpt_icon":0},{"id":"2441045704","title":"Investors Holding Back On Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2441045704","media":"Simply Wall St.","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2441045704?lang=en_us&edition=fundamental","pubTime":"2024-06-08 00:09","pubTimestamp":1717776598,"startTime":"0","endTime":"0","summary":"Harmony Biosciences Holdings, Inc.'s ( NASDAQ:HRMY ) price-to-earnings (or \"P/E\") ratio of 12.6x might make it look...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-hrmy/harmony-biosciences-holdings/news/investors-holding-back-on-harmony-biosciences-holdings-inc-n","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PSQ","NDAQ","MNQmain","TQQQ","LU2210149790.SGD","LU2210150020.SGD","QLD",".IXIC","SQQQ","QID","HRMY","NQmain","BK4588","ISBC","BK4007","BK4112","BK4211","BK4585","LU2095319765.USD","QQQ"],"gpt_icon":0},{"id":"2441947087","title":"Maintaining Buy Rating for Harmony Biosciences Amid Positive Market Outlook and Sustained Growth Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2441947087","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2441947087?lang=en_us&edition=fundamental","pubTime":"2024-06-06 18:28","pubTimestamp":1717669690,"startTime":"0","endTime":"0","summary":"Analyst Graig Suvannavejh from Mizuho Securities maintained a Buy rating on Harmony Biosciences Holdings (HRMY – Research Report) and keeping the p...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/maintaining-buy-rating-for-harmony-biosciences-amid-positive-market-outlook-and-sustained-growth-potential?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/maintaining-buy-rating-for-harmony-biosciences-amid-positive-market-outlook-and-sustained-growth-potential?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","HRMY"],"gpt_icon":0},{"id":"2441722069","title":"BRIEF-Harmony Biosciences Presents Positive Data For Pitolisant In The Treatment Of Excessive Daytime Sleepiness And Fatigue In Myotonic Dystrophy Type 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2441722069","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2441722069?lang=en_us&edition=fundamental","pubTime":"2024-06-05 20:08","pubTimestamp":1717589323,"startTime":"0","endTime":"0","summary":"June 5 (Reuters) - Harmony Biosciences Holdings Inc :   * HARMONY BIOSCIENCES PRESENTS POSITIVE DATA FOR PITOLISANT IN THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS AND FATIGUE IN MYOTONIC DYSTROPHY TYPE 1Source text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HRMY"],"gpt_icon":0},{"id":"2441224220","title":"HARMONY BIOSCIENCES PRESENTS POSITIVE DATA FOR PITOLISANT IN THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS AND FATIGUE IN MYOTONIC DYSTROPHY TYPE 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2441224220","media":"PR Newswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2441224220?lang=en_us&edition=fundamental","pubTime":"2024-06-05 20:05","pubTimestamp":1717589100,"startTime":"0","endTime":"0","summary":"Phase 2 signal detection study presented at the annual meeting of the Associated Professional Sleep Societies, \"SLEEP 2024\". PLYMOUTH MEETING, Pa., June 5, 2024 /PRNewswire/ -- Harmony Biosciences  presented data from its Phase 2 signal detection study showing that pitolisant reduced excessive daytime sleepiness  and fatigue in adults with Myotonic dystrophy Type 1 .Estimates suggest there are 40,000 people currently diagnosed with DM1 in theU.S. with up to 90% of them reporting EDS and fatigue.The Phase 2 signal detection study was a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of pitolisant in the treatment of EDS and other non-muscular symptoms in adults with DM1. Eligible patients were confirmed to have DM1 and enrolled in an 11-week double-blind treatment phase that included a 3-week titration period and an 8-week stable dose period. Participants were randomized to rec","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ZM_gpg5vbHlXilZ5b8i.8A--~B/aD0zMTI7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f7db46efb59308fee209dd80bac82676","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ZM_gpg5vbHlXilZ5b8i.8A--~B/aD0zMTI7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f7db46efb59308fee209dd80bac82676"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/harmony-biosciences-presents-positive-data-120500186.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/harmony-biosciences-presents-positive-data-120500186.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4024","BK4007","HRMY","TYPE","FOR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.harmonybiosciences.com","stockEarnings":[{"period":"1week","weight":0.0013},{"period":"1month","weight":0.0286},{"period":"3month","weight":-0.1015},{"period":"6month","weight":-0.0659},{"period":"1year","weight":-0.1461},{"period":"ytd","weight":-0.0659}],"compareEarnings":[{"period":"1week","weight":-0.0005},{"period":"1month","weight":0.0344},{"period":"3month","weight":0.0404},{"period":"6month","weight":0.145},{"period":"1year","weight":0.2422},{"period":"ytd","weight":0.145}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. It offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.079082},{"month":2,"riseRate":0.5,"avgChangeRate":0.008817},{"month":3,"riseRate":0.5,"avgChangeRate":-0.015849},{"month":4,"riseRate":0,"avgChangeRate":-0.069867},{"month":5,"riseRate":0.5,"avgChangeRate":0.020636},{"month":6,"riseRate":0.75,"avgChangeRate":0.011425},{"month":7,"riseRate":0.666667,"avgChangeRate":-0.009341},{"month":8,"riseRate":0.666667,"avgChangeRate":0.061977},{"month":9,"riseRate":0.5,"avgChangeRate":0.000188},{"month":10,"riseRate":0.75,"avgChangeRate":0.030458},{"month":11,"riseRate":0.75,"avgChangeRate":0.079446},{"month":12,"riseRate":0.5,"avgChangeRate":0.030001}],"exchange":"NASDAQ","name":"Harmony Biosciences Holdings, Inc.","nameEN":"Harmony Biosciences Holdings, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Harmony Biosciences Holdings, Inc.(HRMY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Harmony Biosciences Holdings, Inc.(HRMY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Harmony Biosciences Holdings, Inc.,HRMY,Harmony Biosciences Holdings, Inc.股票,Harmony Biosciences Holdings, Inc.股票老虎,Harmony Biosciences Holdings, Inc.股票老虎国际,Harmony Biosciences Holdings, Inc.行情,Harmony Biosciences Holdings, Inc.股票行情,Harmony Biosciences Holdings, Inc.股价,Harmony Biosciences Holdings, Inc.股市,Harmony Biosciences Holdings, Inc.股票价格,Harmony Biosciences Holdings, Inc.股票交易,Harmony Biosciences Holdings, Inc.股票购买,Harmony Biosciences Holdings, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Harmony Biosciences Holdings, Inc.(HRMY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Harmony Biosciences Holdings, Inc.(HRMY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction